A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA

Sponsor
Hoffman-La Roche

Protocol Number
Hoffman-La Roche GO29383

To Learn More Call
201-510-0910

A Phase 1/2 , Open-Label Safety Pharmacokinetic and Efficacy Stydy of TAS4464 in Patients with Multiple Myeloma or Lymphoma

Type of Cancer
Lymphoma, Multiple Myeloma

Site
Bethesda

Protocol Number
TAS4464-101

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) ( 2nd to 6th Line)

Type of Cancer
Lymphoma

Site
East Brunswick, Howell

Protocol Number
INCB 50465-202

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Type of Cancer
Lymphoma

Site
Howell

Protocol Number
INCB 50465